Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Anticancer Research

• Publication date

  2011-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 22110198
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Use of Silymarin in the Treatment of Liver Diseases

  2012cited by this paper
• 12-O-Tetradecanoyl phorbol-13-acetate (TPA)-induced growth arrest is increased by silibinin by the down-regulation of cyclin B1 and cdc2 and the up-regulation of p21 expression in MDA-MB231 human breast cancer cells.

  2010cited by this paper
• Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth.

  2010cited by this paper
• EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line.

  2009cited by this paper
• Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells.

  2009cited by this paper
• Cancer Chemoprevention Through Dietary Antioxidants: Progress and Promise

  2008cited by this paper
• CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis.

  2007cited by this paper
• Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer

  2006cited by this paper
• CD44 attenuates metastatic invasion during breast cancer progression.

  2005cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• Hyaluronan promotes the malignant phenotype.

  2002cited by this paper
• Flavonoid Antioxidant Silymarin and Skin Cancer

  2002cited by this paper
• CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes.

  2001cited by this paper
• CD44s expression in human colon carcinomas influences growth of liver metastases

  2000cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• CD44: structure, function, and association with the malignant process.

  1997cited by this paper
• AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44

  1997cited by this paper
• Epidermal growth factor modulates cell attachment to hyaluronic acid by the cell surface glycoprotein CD44

  1996cited by this paper
• In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals

  1995cited by this paper
• Glycoprotein CD44 expression and its association with survival in breast cancer.

  1993cited by this paper
• Splicing choice from ten variant exons establishes CD44 variability.

  1993cited by this paper
• De-novo expression of CD44 and survival in gastric cancer.

  1993cited by this paper
• Breast cancer (1)

  1992cited by this paper

• Chemotherapeutic activity of silymarin combined with niclosamide in MCF-7 human breast cancer cell line

  2025cites this paper
• CD44/PD-L1-mediated networks in drug resistance and immune evasion of breast cancer stem cells: Promising targets of natural compounds.

  2024cites this paper
• Serving up health: How phytochemicals transform food into medicine in the battle against cancer

  2024cites this paper
• Unravelling the role of Silibinin in targeting CD44+ cancer stem cells: Therapeutic implications, effective strategies and approaches

  2024influential citation
• A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment

  2024cites this paper
• The role of miR-133a in silibinin-mediated inhibition of the PI3K/AKT/mTOR pathway in MCF-7 breast carcinoma cells

  2024cites this paper
• Targeting beta-catenin signaling for prevention of colorectal cancer - Nutraceutical, drug, and dietary options.

  2023cites this paper
• Spectroscopic analysis, NBO, HOMO and LUMO analysis of anticancer compound Silibinin: experimental and theoretical approach

  2022cites this paper
• Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions

  2022cites this paper
• Safety and Efficacy Assessments to Take Antioxidants in Glioblastoma Therapy: From In Vitro Experiences to Animal and Clinical Studies.

  2021cites this paper
• Silybum marianum, antioxidant activity, and cancer patients

  2021cites this paper
• Silibinin induces metabolic crisis in triple‐negative breast cancer cells by modulating EGFR‐MYC‐TXNIP axis: potential therapeutic implications

  2020cites this paper
• Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis

  2020cites this paper
• Cancer stem cells and nanomedicine: new opportunities to combat multidrug resistance?

  2020cites this paper
• Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance.

  2020cites this paper
• Natural dietary antioxidants containing flavonoids modulate keratinocytes physiology: In vitro tri-culture models.

  2019cites this paper
• Silymarin antiproliferative and apoptotic effects: Insights into its clinical impact in various types of cancer

  2019cites this paper
• Silibinin, A Natural Blend In Polytherapy Formulation For Targeting Cd44v6 Expressing Colon Cancer Stem Cells

  2018cites this paper
• Necessity of In Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients with Equivocal HER2 Immunohistochemistry Results

  2018cites this paper
• Silibinin in human breast cancer: Scope beyond placebo!

  2017cites this paper
• Dietary phytochemicals for possible preventive and therapeutic option of uterine fibroids: Signaling pathways as target

  2017cites this paper
• The apoptotic effects of silibinin on MDA-MB-231 and MCF-7 human breast carcinoma cells

  2017cites this paper
• EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion

  2017cites this paper
• Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression

  2016cites this paper
• Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.

  2016cites this paper
• Silibinin in cancer therapy : A promising prospect

  2016cites this paper
• Docking and ADME/T analysis of silibinin as a potential inhibitor of EGFR kinase for ovarian cancer therapy -

  2016cites this paper
• Pivotal Role of Chemokine Receptor Signaling Axis and Natural Bioactive Chemopreventive Agents in Metastasis of Breast Cancer

  2016cites this paper
• A Promising CAM Therapeutic For Multiple Cancers: Milk Thistle (Silybum)

  2015cites this paper
• Complementary/Alternative Medicine Strategies for Prevention and or Cure of Breast Cancer: A Review

  2015cites this paper
• A novel role of sphingosine kinase‐1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma

  2015cites this paper
• Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals

  2015cites this paper
• Silibinin, a novel chemokine receptor type 4 antagonist, inhibits chemokine ligand 12-induced migration in breast cancer cells.

  2014cites this paper
• Anticancer effect of silibinin on the xenograft model using MDA-MB-468 breast cancer cells

  2014cites this paper
• Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.

  2014cites this paper
• Co-delivery of natural metabolic inhibitors in a self-microemulsifying drug delivery system for improved oral bioavailability of curcumin

  2014cites this paper
• Silibinin Induces Cell Death through Reactive Oxygen Species–Dependent Downregulation of Notch-1/ERK/Akt Signaling in Human Breast Cancer Cells

  2014cites this paper
• Study of the Effect of Silymarin on Viability of Breast Cancer Cell Lines

  2014cites this paper
• Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells.

  2014cites this paper
• Silibinin induces cell death through ROS-dependent down-regulation of Notch-1/ERK/Akt signaling in human breast cancer cells

  2014cites this paper
• Epidermal growth factor‐induced cellular invasion requires sphingosine‐1‐phosphate/sphingosine‐1‐phosphate 2 receptor‐mediated ezrin activation

  2013cites this paper
• Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness.

  2013cites this paper
• Molecular Mechanisms of Silibinin-Mediated Cancer Chemoprevention with Major Emphasis on Prostate Cancer

  2013cites this paper
• Chemoprevention of breast cancer by dietary compounds.

  2012cites this paper
• Isolation and Characterization of Adult Progenitor Cells From Healthy and Laminitic Hoof Tissue

  2012cites this paper
• Power from the garden: plant compounds as inhibitors of the hallmarks of cancer.

  2012cites this paper
• Differential Effect of Growth Factors on Invasion and Proliferation of Endocrine Resistant Breast Cancer Cells

  2012cites this paper
• Diet, nutrients, phytochemicals, and cancer metastasis suppressor genes

  2012cites this paper